Literature DB >> 23072522

A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.

R Chinnock1, S A Webber, A I Dipchand, R N Brown, J F George.   

Abstract

The objective was to determine the incidence and hazard for posttransplant lymphoproliferative disease (PTLD) in a study of 3170 pediatric primary heart transplants between 1993 and 2009 at 35 institutions in the Pediatric Heart Transplant Study. 147 of 151 reported malignancy events were classified as PTLD. Overall freedom from PTLD was 98.5% at 1 year, 94% at 5 years and 90% at 10 years. Freedom from PTLD was lowest in children (ages 1 to < 10 years) versus infants (<1 year) and adolescents (10 to < 18 years) with children at highest risk for PTLD with a relative risk of 2.4 compared to infants and 1.7 compared to adolescents. Positive donor EBV status was a strong risk factor for PTLD in the seronegative recipient, but risk magnitude was dependent on recipient age at the time of transplantation. Nearly 25% of EBV seronegative recipients of EBV+ donors at ages 4-7 at transplantation developed some form of PTLD. The overall risk for PTLD declined in the most recent transplant era (2001-2009, p = 0.003). These findings indicate that EBV status and the age of the recipient at the time of transplantation are important variables in the development of PTLD in the pediatric heart transplant recipient. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2012        PMID: 23072522     DOI: 10.1111/j.1600-6143.2012.04197.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

1.  Surgical management of unilateral oophorectomy for ovarian tissue cryopreservation in high-risk children and adolescents with varied backgrounds.

Authors:  Seido Takae; Shigeyuki Furuta; Dai Keino; Eriko Shiraishi; Yuriko Iwahata; Kei Oyama; Hideyuki Iwahata; Yuri Nishiya; Kohei Kawaguchi; Juma Obayashi; Kunihide Tanaka; Shino Sawada; Yuki Suzuki; Yodo Sugishita; Imari Deura; Yuki Horage; Hideki Nagae; Haruhiro Kondo; Miki Sakamoto; Tetsuya Mori; Hiroaki Kitagawa; Nao Suzuki
Journal:  Pediatr Surg Int       Date:  2021-04-14       Impact factor: 1.827

Review 2.  Pediatric heart transplantation: long-term outcomes.

Authors:  Anne I Dipchand; Jessica A Laks
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-05-29

3.  Neonatal heart transplantation.

Authors:  Mohan John; Leonard L Bailey
Journal:  Ann Cardiothorac Surg       Date:  2018-01

Review 4.  Pediatric heart transplantation-indications and outcomes in the current era.

Authors:  Philip T Thrush; Timothy M Hoffman
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

5.  Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.

Authors:  Don Hayes; Christopher K Breuer; Edwin M Horwitz; Andrew R Yates; Joseph D Tobias; Toshiharu Shinoka
Journal:  Pediatr Cardiol       Date:  2015-07-18       Impact factor: 1.655

Review 6.  Malignancies after pediatric kidney transplantation: more than PTLD?

Authors:  Martin Mynarek; Kais Hussein; Hans H Kreipe; Britta Maecker-Kolhoff
Journal:  Pediatr Nephrol       Date:  2013-09-24       Impact factor: 3.714

7.  Long-Term Evaluation of Post-transplant Lymphoproliferative Disorders in Paediatric Heart Transplantation in Sao Paulo, Brazil.

Authors:  Adam Arshad; Estela Azeka; Samia Barbar; Raphael Marcondes; Adailson Siqueira; Luiz Benvenuti; Nana Miura; Marcelo Jatene; Vicente Odone Filho
Journal:  Pediatr Cardiol       Date:  2019-09-10       Impact factor: 1.655

Review 8.  Posttransplant lymphoproliferative disease after pediatric solid organ transplantation.

Authors:  Martin Mynarek; Tilmann Schober; Uta Behrends; Britta Maecker-Kolhoff
Journal:  Clin Dev Immunol       Date:  2013-09-24

Review 9.  Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders.

Authors:  R Karbasi-Afshar; S Taheri
Journal:  Iran J Ped Hematol Oncol       Date:  2013-07-22

10.  Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture.

Authors:  Jerome E Tanner; Jing Hu; Caroline Alfieri
Journal:  Cancers (Basel)       Date:  2018-04-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.